Genprex appoints Dr. Berger as CMO and Dr. Kumar as CMTO, effective Sept 27, 2021

Genprex, Inc.

Mark S. Berger, M.D. named Chief Medical Officer; annual base salary $450,000 plus up to 40% bonus and 550k stock option at $2.85/sh.
Hemant Kumar, Ph.D. named Chief Manufacturing and Technology Officer; base salary $325,000 plus up to 40% bonus and 400k stock option at $2.85/sh.
Both roles are newly created; Berger and Kumar report to CEO Rodney Varner.
Berger previously CMO at Actinium Pharmaceuticals; Kumar most recently VP at Arcturus Therapeutics.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark S. Berger, M.D.

Chief Medical Officer

GNPX · Genprex, Inc.

Effective: 2021-09-27
Filed: September 28, 2021, 7:59 PM ET

Effective as of September 27, 2021, the Board of Directors (the "Board") of Genprex, Inc. ("Genprex") appointed Mark S. Berger, M.D. as Chief Medical Officer of Genprex.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark S. Berger, M.D. was appointed as Chief Medical Officer at Genprex, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Effective as of September 27, 2021, the Board of Directors (the "Board") of Genprex, Inc. ("Genprex") appointed Mark S. Berger, M.D. as Chief Medical Officer of Genprex.

View on SEC.gov

Genprex, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-21-022771

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.